Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells

Abstract

The objectives of this study were to investigate the effects of the CRISPR/Cas9 system mediated by the HPV pseudotype virus on SiHa cytobiology behavior by cutting the HPV16 E6 gene selectively and to explore the role of this system in the treatment of cervical cancer. After designing specific gRNA sequences targeting HPV16 E6, generating hCas9-EGFP and E6-gRNA-RFP plasmids, and preparing the pseudovirus of HPV16 carrying E6-gRNA and Cas9 plasmids, we determined the titer of the pseudotype virus using the TCID50 method. We obtained the pseudotype virus of HPV16 carrying E6-gRNA and Cas9 plasmids to transfect cervical cancer SiHa cells. Experimental subjects were divided into control group, empty virus group, E6-gRNA transfected group, Cas9 transfected group and Cas9+E6-gRNA transfected group. The molecular size of the cutting sequence was detected using the T7E1 enzyme digestion method and agarose gel electrophoresis, and the cleavage function of CRISPR/Cas9 on the E6 gene was determined at the same time. RT-PCR and Western blotting were performed to detect the mRNA and protein expression levels of E6 in all the groups; the Transwell cell migration assay was performed to detect the cell migration ability and metastasis in all groups. Heterotopic transplantation tumors were incorporated into mice and were used to investigate the effects of the CRISPR/Cas9 system mediated by the HPV pseudovirus on the tumorigenic ability of SiHa cells by selectively cutting HPV16 E6. The HPV16 pseudotype virus carrying E6-gRNA and Cas9 plasmids could successfully infect SiHa cells, and there were two cutting zones in the Cas9+E6-gRNA transfected group. However, the empty virus group, E6-gRNA transfected group and Cas9 transfected group had no corresponding zone. Compared with those in the control group, the empty virus group, E6-gRNA transfected group and Cas9 transfected group, the mRNA and protein expression levels of E6 in SiHa cells were downregulated in the Cas9+E6-gRNA transfected group (P<0.01). In addition, the proliferation and migration abilities of SiHa cells were significantly inhibited (P<0.01). There were no significant differences among the other groups. In contrast to the control group, the HPV pseudotype virus carrying E6-gRNA and Cas9 plasmids could significantly delay the growth of tumor cells of the ectopic tumor transplantation model (P<0.01). The CRISPR/Cas9 system mediated by the HPV pseudotype virus to knockout E6 gene expression exhibited a clear inhibitory effect on the biological function of SiHa cells, which indicated that knocking out the E6 gene using the CRISPR/Cas9 system mediated by the HPV pseudotype virus had a potential effect of eliminating HPV infection and inhibiting the growth of HPV-related tumors. Taken together, these findings provide insight into a new treatment strategy for the prevention and treatment of hr-HPV infected disease, particularly in HPV-related tumors.

Keywords

HPV pseudotype virus / CRISPR/Cas9 / E6 gene / cervical cancer

References

[1] TorreLA, BrayF, SiegelRL, et al.. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108

[2] DoorbarJ. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond), 2006, 110(5): 525-541

[3] SasanoH, YazdanoS, KasajimaA. WHO classification of pancreatic neuroendocrine tumor: overview. Nihon Rinsho, 2015, 73(3): 321-326

[4] LiK, JinX, FangY, et al.. Correlation between physical status of human papilloma virus and cervical carcinogenesis. J Huazhong Univ Sci Technolog Med Sci, 2012, 32(1): 97-102

[5] HopmanAH, TheelenW, HommelbergPP, et al.. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol, 2006, 210(4): 412-419

[6] MelsheimerP, VinokurovaS, WentzensenN, et al.. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res, 2004, 10(9): 3059-3063

[7] MurphyN, RingM, KillaleaAG, et al.. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol, 2003, 56(1): 56-63

[8] KlaesR, BennerA, FriedrichT, et al.. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol, 2002, 26(11): 1389-1399

[9] LinSR, YangHC, KuoYT, et al.. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids, 2014, 3(8): e186

[10] YuenKS, ChanCP, WongNH, et al.. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol, 2015, 96: 626-636

[11] WangJ, QuakeSR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci USA, 2014, 111(36): 13157-13162

[12] KennedyEM, KornepatiAV, GoldsteinM, et al.. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol, 2014, 88(20): 11965-11972

[13] GaoF, ShenXZ, JiangF, et al.. DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol, 2016, 34(7): 768-773

[14] BuckCB, PastranaDV, LowyDR, et al.. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med, 2005, 119: 445-462

[15] StemmerM, ThumbergerT D S, KeyerM, et al.. CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. PLoS One, 2015, 10(4): e0124633

[16] D’CostaZJ, JollyC, AndrophyEJ, et al.. Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. PLoS One, 2012, 7(11): e48954

[17] EbinaH, MisawaN, KanemuraY, et al.. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep, 2013, 3: 2510

[18] GajT, GersbachCA, BarbasCF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 2013, 31(7): 397-405

[19] HsuPD, LanderES, ZhangF. Development and applications of CRISPR-Cas9 for genome engineering. Cell, 2014, 157(6): 1262-1278

[20] PlattRJ, ChenS, ZhouY, et al.. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell, 2014, 159(2): 440-455

[21] XueW, ChenS, YinH, et al.. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514(7522): 380-384

[22] MatanoM, DateS, ShimokawaM, et al.. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med, 2015, 21(3): 256

[23] HecklD, KowalczykMS, YudovichD, et al.. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol, 2014, 32(9): 941-946

[24] WangH, YangH, ShivalilaCS, et al.. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 2013, 153(4): 910-918

[25] NaldiniL. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol, 1998, 9(5): 457-463

[26] StewarSA, DykxhoornDM, PalliserD, et al.. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 2003, 9(4): 493-501

[27] KirnbauerR, TaubJ, GreenstoneH, et al.. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 1993, 67(12): 6929-6936

[28] ZhouJ, SunXY, StenzelDJ, et al.. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185(1): 251-257

[29] CombelasN, SaussereauE, FleuryMJ, et al.. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J Transl Med, 2010, 8: 28

[30] FaheyLM, RaffA D, SilvaDM, et al.. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol, 2009, 183(10): 6151-6156

[31] BuckCB, PastranaDV, LowyDR, et al.. Efficient intracellular assembly of papillomaviral vectors. J Virol, 2004, 78(2): 751-757

[32] HungCF, ChiangAJ, TsaiHH, et al.. Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene. PLoS One, 2012, 7(7): e40983-e40990

[33] Kimchi-SarfatyC, VieiraWD, DoddsD, et al.. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther, 2006, 13(7): 648-657